Metagenomi (MGX)

• Market cap: $102M
• 1 day: 4.21%
• 5 days: -8.42%
• 1 month: -32.17%
• 3 months: 41.67%
• 6 months: -39.15%
• Year to date: -28.23%
• 1 year: -73.62%
• 5 years: -73.62%
• 10 years: -73.62%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).

Employees: 207

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

130% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 10

82% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 11

23% more funds holding

Funds holding: 53 [Q2] → 65 (+12) [Q3]

2.45% less ownership

Funds ownership: 31.11% [Q2] → 28.67% (-2.45%) [Q3]

51% less capital invested

Capital invested by funds: $47.4M [Q2] → $23.2M (-$24.1M) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $14 415% upside
• Avg. target: $14.50 433% upside
• High target: $15 451% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor 26% 1-year accuracy 43 / 165 met price target	415% upside $14	Buy Maintained	10 Dec 2024
Chardan Capital Geulah Livshits 8% 1-year accuracy 4 / 49 met price target	451% upside $15	Buy Maintained	20 Nov 2024